

Minutes for the Institutional Biosafety Committee Meeting

Tuesday, April 14, 2026

Google Online Meeting

1:00 pm - 1:30 pm

Committee Members Present:

Dr. Robert Marr, , Dr. Patricia Loomis, Dr. David Everly, Mr. Nikolas Vistine
Dr. William Conrad, Mr. Sebastian Rodriguez, Mr. Matthew Anagnostopoulos

Committee Members Absent:

Mr. Paul Huber, Dr. Fabio Re, Ms. Jacquelyn Casler, Dr. Joseph Reynolds

Public Attendees Present:

There were no requests from the public to attend this meeting

Call to Order

The meeting was called to order:

Dr. Robert Marr called the Institutional Biosafety Committee meeting to order at 1:06 pm with a quorum of committee members present.

Review of previous IBC Meeting Minutes

The IBC Committee reviewed the following Institutional Biosafety Meeting Minutes:

- The IBC members reviewed the November 11, 2025 meeting minutes.

Dr. Robert Marr recommended a motion for the IBC members to approve the November 11, 2025 meeting minutes as written.

Motion to approve the November 11, 2025 meeting minutes:

First motion: Dr. David Everly

Second motion: Dr. William Conrad

The IBC members unanimously approved the November 11, 2025 meeting minutes as written.

New Business

- Dr. Erin Howe submitted a significant amendment to the current Recombinant / Synthetic Nucleic Acid Molecules Lab Specific Protocol for her lab for IBC members to review and approve. The committee reviewed the significant amendment to Dr. Erin Howe's lab protocol and recommended the following additions and changes:
 - This significant amendment was required for this lab because there is an addition to a new gene vector system
 1. The committee members requested Dr. Howe to include the source(s) for the recombinant PRV.
 2. The committee asked Dr Howe to Indicate "Yes" for Pathogen Genome since most of the PRV genome is intact.
 3. Committee members indicated for location IRP 451, to indicate which sub-bays will be used.

Dr. Marr made a motion to tentatively approve Dr. Erin Howe's significant change to her Recombinant / Synthetic Nucleic Molecules Lab Specific Protocol. After the changes have been completed Dr. Marr will provide a final approval and will share the updates with the committee at the next meeting.

First motion to approve: Dr. William Conrad

Second motion to approve: Dr. David Everly

The IBC members unanimously tentatively approved Dr. Erin Howe's significant amendment to the Recombinant / Synthetic Nucleic Acid Molecules Lab Specific Protocol after Dr. Howe has completed the changes, Dr. Marr will initiate the final approval.

- Dr. Hongkyun Kim submitted a Lab Specific Recombinant / Synthetic Nucleic Acid Molecules protocol for IBC members to review and approve for his lab.
 - Dr. Hongkyun Kim's lab protocol will elevate from a level one to level two which requires a new protocol submittal to the IBC members for review and approval.
 - Committee members noted that on Page 2 – there is no signature required in one area
 - The committee reviewed Dr. Kim's Recombinant / Synthetic Nucleic Acid Molecules Research Lab Protocol and the Core Flow Cytometry Form.
 - The committee had no recommendations for edits to either of the documents submitted for review and approval.

Dr. Marr made a motion to approve Dr. Hongkyun Kim's Recombinant / Synthetic Nucleic Molecules Lab Specific Protocol and the Core Flow Cytometry Form as written with no edits.

First motion to approve: Dr. David Everly

Second motion to approve: Mr. Sebastian Rodriguez

The IBC members unanimously approved Dr. Hongkyun Kim's Recombinant / Synthetic Nucleic Acid Molecules Lab Specific Protocol and the Core Flow Cytometry Form as written with no changes.

Old Business

- There was no old business to discuss.

Other Business

- Dr. Marr reminded IBC members to complete the required CITI training.

Adjourn

- With there being no further business to discuss, Dr. Marr recommended a motion to adjourn the meeting at 1:29 pm. The IBC committee unanimously approved the adjournment of the meeting.